Hypoxia-inducible factor 1 is activated by dysregulated cyclin E during mammary epithelial morphogenesis

Molecular and Cellular Biology

Volumn 31, Issue 18, 2011, Pages 3885-3895

  Sengupta, Tanushri ^a   Abraham, Gathi ^a   Xu, Yanfei ^a   Clurman, Bruce E ^b   Minella, Alex C ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; EGLN 1 PROTEIN; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MEMBRANE PROTEIN; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

ACINAR CELL; ANIMAL CELL CULTURE; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CELL AGING; CELL PROLIFERATION; CONTROLLED STUDY; DEREGULATION; GENE EXPRESSION; HUMAN; IN VITRO STUDY; MORPHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION;

ANIMALS; BREAST NEOPLASMS; CELL AGING; CELL CYCLE; CELL LINE; CHROMATIN IMMUNOPRECIPITATION; CYCLIN E; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; E2F TRANSCRIPTION FACTORS; FEMALE; HEK293 CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MAMMARY GLANDS, ANIMAL; MAMMARY GLANDS, HUMAN; MICE; RNA INTERFERENCE; RNA, SMALL INTERFERING;

MURINAE;

EID: 80052565462     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.05089-11     Document Type: Article

References (53)

1. Bartkova, J., et al. 2005. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434:864-870.
2. Bartkova, J., et al. 2006. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444:633-637.
3. Bornstein, G., et al. 2003. Role of the SCFSkp2 ubiquitin ligase in the degradation of p21Cip1 in S phase. J. Biol. Chem. 278:25752-25757.
4. Carmeliet, P., et al. 1998. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394:485-490.
5. Chen, Z., V. B. Indjeian, M. McManus, L. Wang, and B. D. Dynlacht. 2002. CP110, a cell cycle-dependent CDK substrate, regulates centrosome duplication in human cells. Dev. Cell 3:339-350.
6. Chong, J. L., et al. 2009. E2F1-3 switch from activities in progenitor cells to repressors in differentiating cells. Nature 462:930-934.
7. Clurman, B. E., R. J. Sheaff, K. Thress, M. Groudine, and J. M. Roberts. 1996. Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. Genes Dev. 10:1979-1990.
8. Debnath, J., and J. S. Brugge. 2005. Modelling glandular epithelial cancers in three-dimensional cultures. Nat. Rev. Cancer 5:675-688.
9. Debnath, J., S. K. Muthuswamy, and J. S. Brugge. 2003. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 30:256-268.
10. Di Micco, R., et al. 2006. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 444:638-642.
11. Dimri, G. P., et al. 1995. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. U. S. A. 92:9363-9367.
12. Ekholm-Reed, S., et al. 2004. Deregulation of cyclin E in human cells interferes with prereplication complex assembly. J. Cell Biol. 165:789-800.
13. Gardner, L. B., et al. 2001. Hypoxia inhibits G1/S transition through regulation of p27 expression. J. Biol. Chem. 276:7919-7926.
14. Geng, Y., et al. 2003. Cyclin E ablation in the mouse. Cell 114:431-443.
15. Goda, N., et al. 2003. Hypoxia-inducible factor 1alpha is essential for cell cycle arrest during hypoxia. Mol. Cell. Biol. 23:359-369.
16. Grim, J. E., et al. 2008. Isoform- and cell cycle-dependent substrate degradation by the Fbw7 ubiquitin ligase. J. Cell Biol. 181:913-920.
17. Hinds, P. W., et al. 1992. Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell 70:993-1006.
18. Huang, H., K. M. Regan, Z. Lou, J. Chen, and D. J. Tindall. 2006. CDK2-dependent phosphorylation of FOXO1 as an apoptotic response to DNA damage. Science 314:294-297.
19. Hwang, H. C., and B. E. Clurman. 2005. Cyclin E in normal and neoplastic cell cycles. Oncogene 24:2776-2786.
20. 2 sensing. Science 292:464-468.
21. 2-regulated prolyl hydroxylation. Science 292: 468-472.
22. Jiang, Y., et al. 2009. An algorithm for identifying novel targets of transcription factor families: application to hypoxia-inducible factor 1 targets. Cancer Inform. 7:75-89.
23. Keyomarsi, K., S. L. Tucker, and I. Bedrosian. 2003. Cyclin E is a more powerful predictor of breast cancer outcome than proliferation. Nat. Med. 9:152.
24. Keyomarsi, K., et al. 2002. Cyclin E and survival in patients with breast cancer. N. Engl. J. Med. 347:1566-1575.
25. Koepp, D. M., et al. 2001. Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science 294:173-177.
26. Koshiji, M., et al. 2004. HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. EMBO J. 23:1949-1956.
27. Le Beyec, J., et al. 2007. Cell shape regulates global histone acetylation in human mammary epithelial cells. Exp. Cell Res. 313:3066-3075.
28. Lee, G. Y., P. A. Kenny, E. H. Lee, and M. J. Bissell. 2007. Three-dimensional culture models of normal and malignant breast epithelial cells. Nat. Methods 4:359-365.
29. Liu, E., X. Li, F. Yan, Q. Zhao, and X. Wu. 2004. Cyclin-dependent kinases phosphorylate human Cdt1 and induce its degradation. J. Biol. Chem. 279: 17283-17288.
30. Loeb, K. R., et al. 2005. A mouse model for cyclin E-dependent genetic instability and tumorigenesis. Cancer Cell 8:35-47.
31. Ma, Y., et al. 2007. Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas. Proc. Natl. Acad. Sci. U. S. A. 104:4089-4094.
32. Mailand, N., and J. F. Diffley. 2005. CDKs promote DNA replication origin licensing in human cells by protecting Cdc6 from APC/C-dependent proteolysis. Cell 122:915-926.
33. Majumder, P. K., et al. 2008. A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell 14:146-155.
34. Minella, A. C., J. E. Grim, M. Welcker, and B. E. Clurman. 2007. p53 and SCFFbw7 cooperatively restrain cyclin E-associated genome instability. Oncogene 26:6948-6953.
35. Minella, A. C., et al. 2008. Cyclin E phosphorylation regulates cell proliferation in hematopoietic and epithelial lineages in vivo. Genes Dev. 22:1677-1689.
36. Minella, A. C., et al. 2002. p53 and p21 form an inducible barrier that protects cells against cyclin E-cdk2 deregulation. Curr. Biol. 12:1817-1827.
37. Mizushima, N., T. Yoshimori, and B. Levine. 2010. Methods in mammalian autophagy research. Cell 140:313-326.
38. Moroni, M. C., et al. 2001. Apaf-1 is a transcriptional target for E2F and p53. Nat. Cell Biol. 3:552-558.
39. Moroy, T., and C. Geisen. 2004. Cyclin E. Int. J. Biochem. Cell Biol. 36: 1424-1439.
40. Okuda, M., et al. 2000. Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell 103:127-140.
41. Ovcharenko, I., M. A. Nobrega, G. G. Loots, and L. Stubbs. 2004. ECR Browser: a tool for visualizing and accessing data from comparisons of multiple vertebrate genomes. Nucleic Acids Res. 32:W280-W286.
42. Rabinovich, A., V. X. Jin, R. Rabinovich, X. Xu, and P. J. Farnham. 2008. E2F in vivo binding specificity: comparison of consensus versus nonconsensus binding sites. Genome Res. 18:1763-1777.
43. Rajagopalan, H., et al. 2004. Inactivation of hCDC4 can cause chromosomal instability. Nature 428:77-81.
44. Saavedra, H. I., et al. 2003. Inactivation of E2F3 results in centrosome amplification. Cancer Cell 3:333-346.
45. Semenza, G. L. 2010. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29:625-634.
46. Sheaff, R. J., M. Groudine, M. Gordon, J. M. Roberts, and B. E. Clurman. 1997. Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev. 11:1464-1478.
47. Smith, A. P., et al. 2006. Deregulated cyclin E promotes p53 loss of heterozygosity and tumorigenesis in the mouse mammary gland. Oncogene 25:7245-7259.
48. Strohmaier, H., et al. 2001. Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature 413:316-322.
49. Subramanian, A., et al. 2005. Gene set enrichment analysis: a knowledgebased approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U. S. A. 102:15545-15550.
50. Thomas, D. M., et al. 2004. Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma. J. Cell Biol. 167:925-934.
51. Welcker, M., and B. E. Clurman. 2008. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat. Rev. Cancer 8:83-94.
52. Welcker, M., et al. 2003. Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation. Mol. Cell 12:381-392.
53. Zhao, J., et al. 2000. NPAT links cyclin E-Cdk2 to the regulation of replication-dependent histone gene transcription. Genes Dev. 14:2283-2297.